Proteus Biomedical (Redwood City, California) certainly is not the only company looking at how to improve the measurement of cardiac performance in heart failure patients. But, according to Andrew Thompson, CEO and co-founder of Proteus, "everybody else" has come up with a new lead and/or a new procedure."